Boehringer Ingelheim has entered an agreement with Quallent Pharmaceuticals, a private label pharmaceutical distributor, to help expand patient access to citrate-free adalimumab-adbm, Boehringer’s biosimilar to Humira (adalimumab), in the U.S.   Under the terms of the agreement, Boehringer Ingelheim will manufacture adalimumab-adbm for Quallent. Boehringer Ingelheim will continue to commercialize Boehringer Ingelheim-labeled Cyltezo (adalimumab-adbm) injection and Adalimumab-adbm.   &#...